|
KMID : 1151620170020010012
|
|
Journal of Retina
2017 Volume.2 No. 1 p.12 ~ p.20
|
|
|
Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity
|
|
Yoo Su-Jin
Kim Jae-Hui
Han Jung-Il
Kim Jong-Woo
Kim Chul-Gu
Lee Dong-Won
|
|
|
Abstract
|
|
|
Purpose: To investigate 2-year treatment outcomes of anti-vascular endothelial growth factor (VEGF) therapy in eyes with polypoidal choroidal vasculopathy (PCV) with good baseline visual acuity.
Methods: This retrospective, observational study included 21 eyes (10 eyes with a subfoveal polyp, 11 eyes with an extrafoveal polyp) of 21 subjects diagnosed with PCV. All eyes had a baseline best-corrected visual acuity (BCVA) of 20/25 or better and were administered an initial treatment of three intravitrial anti-VEGF injections at one-month intervals. Additional anti-VEGF treatments were administered as needed for recurring cases. BCVA and central foveal thickness (CFT) obtained 24 months after diagnosis were compared with baseline values.
Results: Mean logarithm of the minimal angle of resolution (logMAR) BCVA was 0.07 ± 0.04 at baseline and 0.19 ± 0.29 approximately 24 months after initial diagnosis, a slight difference that was not statistically significant (p = 0.560). Of the 21 eyes included, 17 eyes (80.9%) had stable vision and 4 eyes (19.0%) had a ≥0.2 deterioration in logMAR BCVA. Twenty-four-month CFT (212.9 ± 76.1 ?m) was significantly lower than baseline CFT (324.6 ± 121.2 ?m, p = 0.015).
Conclusions: Two-year visual outcomes following anti-VEGF therapy in eyes with PCV and good initial visual acuity were generally favorable. However, logMAR BCVA deteriorated by ≥0.2 in 19.0% of treated eyes.
|
|
|
KEYWORD
|
|
|
Anti-vascular endothelial growth factor, Good visual acuity, Long-term, Polypoidal choroidal vasculopathy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|